Edition:
United Kingdom

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

2,384JPY
24 Jun 2016
Change (% chg)

¥-174 (-6.80%)
Prev Close
¥2,558
Open
¥2,559
Day's High
¥2,588
Day's Low
¥2,339
Volume
3,721,900
Avg. Vol
2,793,737
52-wk High
¥2,769
52-wk Low
¥1,972

4568.T

Chart for 4568.T

About

DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the... (more)

Overall

Beta: 0.90
Market Cap(Mil.): ¥1,689,929.00
Shares Outstanding(Mil.): 709.01
Dividend: 35.00
Yield (%): 2.52

Financials

  4568.T Industry Sector
P/E (TTM): 20.15 33.11 34.49
EPS (TTM): 118.31 -- --
ROI: 5.02 14.75 14.01
ROE: 6.49 15.86 15.24

BRIEF-Daiichi Sankyo plans 28 mln shares repurchase

* Says it plans to buy 28 million shares (4.1 percent outstanding) back, for up to 500 million yen, from June 21 to Oct. 28

20 Jun 2016

BRIEF-Daiichi Sankyo to buy back up to 50 bln yen of stock

* Daiichi Sankyo says to buy back up to 4.1 percent of own shares worth 50 billion yen ($480 million) Source text for Eikon: Further company coverage: ($1 = 104.5400 yen)

20 Jun 2016

BRIEF-Nitto signs partnership agreement with Daiichi Sankyo

* Signed a partnership agreement with Daiichi Sankyo company, ltd.

10 May 2016

Daiichi buys Japanese rights to UK heart stem cell therapy

LONDON A Welsh stem cell company founded by a Nobel prize winner has signed a partnership deal with Daiichi Sankyo, giving the drugmaker rights to develop its regenerative heart treatment for the Japanese market.

10 May 2016

Daiichi buys Japanese rights to UK heart stem cell therapy

LONDON A Welsh stem cell company founded by a Nobel prize winner has signed a partnership deal with Daiichi Sankyo, giving the drugmaker rights to develop its regenerative heart treatment for the Japanese market.

10 May 2016

Daiichi buys Japanese rights to UK heart stem cell therapy

LONDON, May 10 A Welsh stem cell company founded by a Nobel prize winner has signed a partnership deal with Daiichi Sankyo, giving the drugmaker rights to develop its regenerative heart treatment for the Japanese market.

10 May 2016

BRIEF-Daiichi Sankyo announces outcome of arbitration proceeding with Ranbaxy

* Says Daiichi Sankyo received a final award in the arbitration that it filed with the International Court of Arbitration of the International Chamber of Commerce in November 2012 against the former shareholders Ranbaxy Laboratories Ltd. on May 3

06 May 2016

Morning News Call - India, May 5

To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_05062016.pdf FACTORS TO WATCH 11:00 am: Parliament session continues in New Delhi. 5:00 pm: Niti Aayog Chief Executive Amitabh Kant and DIPP Secretary Ramesh Abhishek at an event in New Delhi. 5:00 pm: RBI to release weekly foreign exchange data in Mumbai. GMF: LIVECHAT- THE WEEKAHEAD - with Reuters markets editor Mike Dolan Join Mike as he goes th

06 May 2016

Japanese drugmaker Daiichi wins damages from former Ranbaxy owners

MUMBAI The former owners of Indian drugmaker Ranbaxy Laboratories have been ordered by an arbitration court to pay damages worth 25.63 billion rupees ($385 million) to Japan's Daiichi Sankyo Co Ltd, they said on Thursday.

05 May 2016

BRIEF-Portola signs agreement with Daiichi Sankyo to develop andexanet alfa as an antidote for edoxaban

* Portola pharmaceuticals enters into clinical collaboration agreement with daiichi sankyo to develop andexanet alfa with edoxaban in japan

04 Apr 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Reuters Investment Profile
£10.00
Provider : MarketLine
£33.00
Provider : GlobalData
£81.00
Provider : GlobalData
£195.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.